Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
15 drugs in development
By Therapeutic Area
top 6
R&D Momentum
83/100
Pipeline Velocity
58/100
Trial Completion Rate
64/100
Pipeline Concentration
14/100
Pipeline Freshness
82/100
Strategic Signals
Activity
Last 14 days
Phase 2 Open-Label Trial Investigating the Efficacy and Safety of Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy
Differences in Muscle Utilization, Tissue Pressure, Cognitive Performance, and Caloric Output Among Active and Passive Sitting Positions.
Remotely-Delivered Cognitive Behavioral Stress Management Effects on Cancer Accelerated Aging in Older, Distressed Breast Cancer Survivors
The Role of Doxycycline in the Management of Postoperative Seromas: A Pilot Study
Use of Magnesium-L-Threonate to Improve Subjective Sleep Quality After Total Joint Arthroplasties: Randomized Controlled Clinical Trial
Targeted Navigation to Achieve Health Equity: Increasing Access to Care, Patient Engagement and Research Participation
Meaning-Centered Grief Therapy for Parents Bereaved by Cancer: A Multisite Randomized Controlled Trial
Tele-Harm Reduction for Rapid Initiation of Antiretrovirals in People Who Inject Drugs: a Randomized Controlled Trial
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)